Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12011629 | 0.87 | HDAC4 (0.55) | GAAHDAC4KDM4ESMN1; SMN2HTT | |
| SCHEMBL12011576 | 0.84 | HDAC4 (0.60) | HDAC4KDM4ESMN1; SMN2RAB9ANPC1 | |
| SCHEMBL24568272 | 0.83 | HDAC4 (0.51) | GAAHDAC4KDM4EEGFRSMN1; SMN2 | |
| SCHEMBL12011608 | 0.82 | HDAC4 (0.48) | GAAHDAC4KDM4ESMN1; SMN2HTT | |
| SCHEMBL17555519 | 0.82 | HDAC4 (0.48) | GAAHDAC4KDM4ESMN1; SMN2HTT | |
| SCHEMBL12011571 | 0.82 | PTPN1 (0.50) | GAAHDAC4KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL20466115 | 0.82 | CA1 (0.47) | GAAHDAC4KDM4ESMN1; SMN2HTT | |
| SCHEMBL3723066 | 0.81 | HDAC4 (0.56) | GAAHDAC4KDM4ESMN1; SMN2HTT | |
| SCHEMBL24568100 | 0.81 | HDAC4 (0.53) | GAAHDAC4KDM4ESMN1; SMN2HTT | |
| SCHEMBL13778299 | 0.81 | ALDH1A1 (0.47) | GAAKDM4ESMN1; SMN2RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2024-04-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3284744-B1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED LLC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200190082-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2020-05-21 | — | — | US | disclosed |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8450340-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011084486-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | GAA 2480/4885HDAC4 1651/4885KDM4E 3982/4885 |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | GAA 2943/4885HDAC4 593/4885KDM4E 1972/4885 |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | GAA 2943/4885HDAC4 593/4885KDM4E 1972/4885 |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | GAA 2480/4885HDAC4 1651/4885KDM4E 3982/4885 |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | GAA 2480/4885HDAC4 1651/4885KDM4E 3982/4885 |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | GAA 2480/4885HDAC4 1651/4885KDM4E 3982/4885 |
| US-20200190082-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | GAA 2480/4885HDAC4 1651/4885KDM4E 3982/4885 |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | GAA 2621/4885HDAC4 1958/4885KDM4E 448/4885 |
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | GAA 4332/4885HDAC4 1388/4885KDM4E 4516/4885 |
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | GAA 2506/4885HDAC4 1125/4885KDM4E 3131/4885 |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | GAA 2480/4885HDAC4 1651/4885KDM4E 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.